INVESTORS

Investor Relations

Recent News
Oct 16, 2017
Sierra Oncology to Report Chk1 Inhibitor SRA737 Preclinical Data at AACR-NCI-EORTC 2017

- Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents, including potentiation by novel low-dose gemcitabine combination, in preclinical models...

Oct 11, 2017
Sierra Oncology to Present at the 2017 BIO Investor Forum

- "Beyond PARP - Next Generation DDR Therapeutics" scheduled for 11:00 am PT on October 17, 2017 - VANCOUVER, Oct 11, 2017 /CNW/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug...

Oct 4, 2017
Sierra Oncology to host Key Opinion Leader Meeting "Beyond PARP: The Clinical Potential of Next Generation DNA Damage Response (DDR) Therapeutics" on October 12th in NY

- Dr. Leonard Post, Dr. Eric J. Brown, and Dr. Geoffrey I. Shapiro to discuss DDR scientific and clinical development - VANCOUVER, Oct. 4, 2017 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical...

View all news releases

Events and Webcasts
BIO Investor Forum, San Francisco
Tuesday, October 17, 2017
11:00am PDT

View all events and webcasts


NASDAQ: SRRANASDAQ: DNAI